Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Context Recent randomized controlled trials (RCTs) examined the role of adding androgen
receptor signaling inhibitors (ARSIs), including abiraterone acetate (ABI), apalutamide …

Background Patients with prostate cancer who have high-risk biochemical recurrence have
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen …

PURPOSE The first interim analysis of the phase III, randomized, placebo-controlled TITAN
study showed that apalutamide significantly improved overall survival (OS) and radiographic …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …

PURPOSE For patients with metastatic hormone-sensitive prostate cancer, metastatic
burden affects outcome. We examined efficacy and safety from the ARASENS trial for …

Background The phase 3 SPARTAN study evaluated apalutamide versus placebo in
patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

Background STAMPEDE has previously reported that the use of upfront docetaxel improved
overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long …

Purpose: The summary presented herein represents Part I of the two-part series dedicated to
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and …